Compare EVTV & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTV | IMRN |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 12.0M |
| IPO Year | 2017 | N/A |
| Metric | EVTV | IMRN |
|---|---|---|
| Price | $2.12 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 25.2M | 60.7K |
| Earning Date | 11-20-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,696,856.00 | ★ $4,777,422.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 113.69 | 48.63 |
| 52 Week Low | $0.33 | $0.68 |
| 52 Week High | $5.07 | $2.39 |
| Indicator | EVTV | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 51.96 | 32.97 |
| Support Level | $1.96 | $0.73 |
| Resistance Level | $2.26 | $0.82 |
| Average True Range (ATR) | 0.33 | 0.05 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 35.69 | 7.09 |
Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.